The FDA said Friday it has issued new fast-track vouchers to three psychedelic companies, and its selections have come as a “surprise” to Wall Street.

Avalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million in net proceeds if

Novartis has withdrawn its EU application for radioligand therapy Pluvicto’s expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication.

The new generation of weight loss medicines does an unprecedented job of keeping off the pounds — if people stay on the drugs. Yet numerous

Sanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from